ArriVent BioPharma Net Income From Continuing Ops Over Time
| AVBP Stock | 23.03 1.41 6.52% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out ArriVent BioPharma Performance and ArriVent BioPharma Correlation. Can Biotechnology industry sustain growth momentum? Does ArriVent have expansion opportunities? Factors like these will boost the valuation of ArriVent BioPharma. If investors know ArriVent will grow in the future, the company's valuation will be higher. Determining accurate worth demands scrutiny of both present operating results and projected expansion capacity. Evaluating ArriVent BioPharma demands reviewing these metrics collectively while recognizing certain factors exert disproportionate influence.
ArriVent BioPharma Common's market price often diverges from its book value, the accounting figure shown on ArriVent's balance sheet. Smart investors calculate ArriVent BioPharma's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Market participants employ diverse analytical approaches to determine fair value and identify buying opportunities when prices dip below calculated worth. Since ArriVent BioPharma's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that ArriVent BioPharma's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether ArriVent BioPharma represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, ArriVent BioPharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income From Continuing Ops Analysis
Compare ArriVent BioPharma Common and related stocks such as MeiraGTx Holdings PLC, Replimune Group, and Astria Therapeutics Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MGTX | (19.8 M) | (19.8 M) | (19.8 M) | (19.8 M) | (19.8 M) | (19.8 M) | (19.8 M) | (31 M) | (82.9 M) | (54.7 M) | (58 M) | (79.6 M) | (130 M) | (131.6 M) | (147.8 M) | (133 M) | (126.4 M) |
| REPL | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (19.7 M) | (30.8 M) | (52.6 M) | (80.9 M) | (118 M) | (174.3 M) | (215.8 M) | (247.3 M) | (222.6 M) | (211.4 M) |
| ATXS | (27.4 M) | (27.4 M) | (27.4 M) | (27.4 M) | (27.4 M) | (27.4 M) | (27.4 M) | (27.4 M) | (25.9 M) | (26.3 M) | (37.3 M) | (194.9 M) | (51.8 M) | (72.9 M) | (94.3 M) | (84.8 M) | (89.1 M) |
| MBX | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (26.1 M) | (32.6 M) | (61.9 M) | (55.7 M) | (58.5 M) |
| DNA | (119.9 M) | (119.9 M) | (119.9 M) | (119.9 M) | (119.9 M) | (119.9 M) | (119.9 M) | (119.9 M) | (119.9 M) | (119.9 M) | (126.7 M) | (1.8 B) | (2.1 B) | (854.3 M) | (547 M) | (492.3 M) | (516.9 M) |
| IOVA | (25.7 M) | (25.7 M) | (3.3 M) | (25.4 M) | (12 M) | (27.7 M) | (52.9 M) | (92.1 M) | (123.6 M) | (197.6 M) | (259.6 M) | (342.3 M) | (395.9 M) | (433 M) | (372.2 M) | (335 M) | (318.2 M) |
| VALN | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | (11.5 M) | 3.3 M | (1.7 M) | (64.4 M) | (73.4 M) | (143.3 M) | (113.5 M) | (12.2 M) | (11 M) | (11.6 M) |
| ERAS | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (12 M) | (101.7 M) | (122.8 M) | (242.8 M) | (230.6 M) | (161.7 M) | (145.5 M) | (152.8 M) |
| ARVN | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (14.4 M) | (24 M) | (41.5 M) | (70.3 M) | (119.3 M) | (191 M) | (282.5 M) | (295.4 M) | (198.9 M) | (179 M) | (188 M) |
| DAWN | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (17 M) | (43.8 M) | (72.8 M) | (142.2 M) | (188.9 M) | (95.5 M) | (85.9 M) | (90.2 M) |
ArriVent BioPharma Common and related stocks such as MeiraGTx Holdings PLC, Replimune Group, and Astria Therapeutics Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| ArriVent BioPharma Common | AVBP |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 18 Campus Boulevard, |
| Exchange | NASDAQ Exchange |
null 23.03
Additional Tools for ArriVent Stock Analysis
When running ArriVent BioPharma's price analysis, check to measure ArriVent BioPharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ArriVent BioPharma is operating at the current time. Most of ArriVent BioPharma's value examination focuses on studying past and present price action to predict the probability of ArriVent BioPharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ArriVent BioPharma's price. Additionally, you may evaluate how the addition of ArriVent BioPharma to your portfolios can decrease your overall portfolio volatility.